Literature DB >> 21153913

Systematic evaluation of the descriptive and predictive performance of paediatric morphine population models.

Elke H J Krekels1, Johan G C van Hasselt, Dick Tibboel, Meindert Danhof, Catherijne A J Knibbe.   

Abstract

PURPOSE: A framework for the evaluation of paediatric population models is proposed and applied to two different paediatric population pharmacokinetic models for morphine. One covariate model was based on a systematic covariate analysis, the other on fixed allometric scaling principles.
METHODS: The six evaluation criteria in the framework were 1) number of parameters and condition number, 2) numerical diagnostics, 3) prediction-based diagnostics, 4) η-shrinkage, 5) simulation-based diagnostics, 6) diagnostics of individual and population parameter estimates versus covariates, including measurements of bias and precision of the population values compared to the observed individual values. The framework entails both an internal and external model evaluation procedure.
RESULTS: The application of the framework to the two models resulted in the detection of overparameterization and misleading diagnostics based on individual predictions caused by high shrinkage. The diagnostic of individual and population parameter estimates versus covariates proved to be highly informative in assessing obtained covariate relationships. Based on the framework, the systematic covariate model proved to be superior over the fixed allometric model in terms of predictive performance.
CONCLUSIONS: The proposed framework is suitable for the evaluation of paediatric (covariate) models and should be applied to corroborate the descriptive and predictive properties of these models.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21153913      PMCID: PMC3063866          DOI: 10.1007/s11095-010-0333-1

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  28 in total

1.  Re-examination of the "3/4-law" of metabolism.

Authors:  P S Dodds; D H Rothman; J S Weitz
Journal:  J Theor Biol       Date:  2001-03-07       Impact factor: 2.691

2.  Curvature in metabolic scaling.

Authors:  Tom Kolokotrones; Eric J Deeds; Walter Fontana
Journal:  Nature       Date:  2010-04-01       Impact factor: 49.962

3.  Metrics for external model evaluation with an application to the population pharmacokinetics of gliclazide.

Authors:  Karl Brendel; Emmanuelle Comets; Céline Laffont; Christian Laveille; France Mentré
Journal:  Pharm Res       Date:  2006-08-12       Impact factor: 4.200

Review 4.  Mechanism-based concepts of size and maturity in pharmacokinetics.

Authors:  B J Anderson; N H G Holford
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

5.  Allometric exponents do not support a universal metabolic allometry.

Authors:  Craig R White; Phillip Cassey; Tim M Blackburn
Journal:  Ecology       Date:  2007-02       Impact factor: 5.499

6.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

7.  Propofol pharmacokinetics and pharmacodynamics for depth of sedation in nonventilated infants after major craniofacial surgery.

Authors:  Mariska Y M Peeters; Sandra A Prins; Catherijne A J Knibbe; Joost DeJongh; Ron H N van Schaik; Monique van Dijk; Ilse P van der Heiden; Dick Tibboel; Meindert Danhof
Journal:  Anesthesiology       Date:  2006-03       Impact factor: 7.892

8.  Evaluating pharmacokinetic/pharmacodynamic models using the posterior predictive check.

Authors:  Y Yano; S L Beal; L B Sheiner
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-04       Impact factor: 2.745

9.  Prediction of drug clearance in children: impact of allometric exponents, body weight, and age.

Authors:  Iftekhar Mahmood
Journal:  Ther Drug Monit       Date:  2007-06       Impact factor: 3.681

10.  Routine morphine infusion in preterm newborns who received ventilatory support: a randomized controlled trial.

Authors:  Sinno H P Simons; Monique van Dijk; Richard A van Lingen; Daniella Roofthooft; Hugo J Duivenvoorden; Niesje Jongeneel; Carin Bunkers; Enna Smink; K J S Anand; John N van den Anker; Dick Tibboel
Journal:  JAMA       Date:  2003-11-12       Impact factor: 56.272

View more
  30 in total

1.  Scaling of pharmacokinetics across paediatric populations: the lack of interpolative power of allometric models.

Authors:  Massimo Cella; Catherijne Knibbe; Saskia N de Wildt; Joop Van Gerven; Meindert Danhof; Oscar Della Pasqua
Journal:  Br J Clin Pharmacol       Date:  2012-09       Impact factor: 4.335

2.  A bodyweight-dependent allometric exponent for scaling clearance across the human life-span.

Authors:  Chenguang Wang; Mariska Y M Peeters; Karel Allegaert; Heleen J Blussé van Oud-Alblas; Elke H J Krekels; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2012-06       Impact factor: 4.200

3.  Developmental pharmacokinetics of propylene glycol in preterm and term neonates.

Authors:  Roosmarijn F W De Cock; Catherijne A J Knibbe; Aida Kulo; Jan de Hoon; Rene Verbesselt; Meindert Danhof; Karel Allegaert
Journal:  Br J Clin Pharmacol       Date:  2013-01       Impact factor: 4.335

4.  Electronic Health Record-Embedded Decision Support Platform for Morphine Precision Dosing in Neonates.

Authors:  Alexander A Vinks; Nieko C Punt; Frank Menke; Eric Kirkendall; Dawn Butler; Thomas J Duggan; DonnaMaria E Cortezzo; Sam Kiger; Tom Dietrich; Paul Spencer; Rob Keefer; Kenneth D R Setchell; Junfang Zhao; Joshua C Euteneuer; Tomoyuki Mizuno; Kevin R Dufendach
Journal:  Clin Pharmacol Ther       Date:  2019-12-11       Impact factor: 6.875

5.  A population pharmacokinetic model of intravenous telavancin in healthy individuals to assess tissue exposure.

Authors:  Sami Ullah; Peter Matzneller; Markus Zeitlinger; Uwe Fuhr; Max Taubert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-05-06       Impact factor: 3.000

6.  Population Pharmacokinetics: Some Observations in Pediatric Modeling for Drug Clearance.

Authors:  Iftekhar Mahmood; Million A Tegenge
Journal:  Clin Pharmacokinet       Date:  2017-12       Impact factor: 6.447

7.  Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysis.

Authors:  Esther J H Janssen; Diane E T Bastiaans; Pyry A J Välitalo; Annemarie M C van Rossum; Evelyne Jacqz-Aigrain; Hermione Lyall; Catherijne A J Knibbe; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

8.  Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

Authors:  Wei Zhao; Massimo Cella; Oscar Della Pasqua; David Burger; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 9.  Paediatric pharmacokinetics: key considerations.

Authors:  Hannah Katharine Batchelor; John Francis Marriott
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335

10.  The allometric exponent for scaling clearance varies with age: a study on seven propofol datasets ranging from preterm neonates to adults.

Authors:  Chenguang Wang; Karel Allegaert; Mariska Y M Peeters; Dick Tibboel; Meindert Danhof; Catherijne A J Knibbe
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.